Varenicline tartrate

Impurities

NP3497

375815-87-5

Varenicline tartrate

Varenicline (trade name Chantix in the USA and Champix in Canada, Europe and other countries, marketed by Pfizer, usually in the form of varenicline tartrate), is a prescription medication used to treat nicotine addiction. Varenicline is a nicotinic receptor partial agonist-it stimulates nicotine receptors more weakly than nicotine itself does. In this respect it is similar to cytisine and different from the nicotinic antagonist, bupropion, and nicotine replacement therapies (NRTs) like nicotine patches and nicotine gum. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms it can assist some patients to quit smoking.

7;8;9;10-tetrahydro-6H-6;10-methanoazepino[4;5-g]quinoxaline (2R;3R)-2;3-dihydroxysuccinate; Champix (TN); 5,8,14-triazatetracyclo[10.3.1.0^2,11.0^4,9]-hexadeca-2(11),3,5,7,9-pentaene L-tartrate; 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine tartrate Champix; CP-526555-18; CP 526555 18; CP52655518; Chantix; Champix

(2R,3R)-2,3-dihydroxybutanedioic acid;5,8,14-triazatetracyclo[10.3.1.0^2,11.0^4,9]hexadeca-2,4,6,8,10-pentaene

361.35

C17H19N3O6

C1C2CNCC1C3=CC4=NC=CN=C4C=C23.C(C(C(=O)O)O)(C(=O)O)O

InChI=1S/C13H13N3.C4H6O6/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1;5-1(3(7)8)2(6)4(9)10/h1-2,4-5,8-9,14H,3,6-7H2;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

TWYFGYXQSYOKLK-LREBCSMRSA-N

400.6 °C at 760 mmHg

206-208 °C

≥ 95%

Soluble in Methanol, DMSO, DMF, Ethanol

Pale Yellow Solid

2-8 °C

1 g